Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood As Indicators for Following the Course of Bladder Cancer

Overview

Journal Immune Netw

Specialty Allergy & Immunology

Date 2014 Jul 8

PMID 24999312

Citations 14

Authors

Rasoul Baharlou

Abbas Ahmadi Vasmehjani

Ali Dehghani

Mohamed Amin Ghobadifar

Mahshid Khoubyari

Affiliations

Soon will be listed here.

Abstract

Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-β) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-β were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p<0.0001) and TGF-β (p<0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.

Citing Articles

Interleukin-17 promotes the development of ovarian cancer through upregulation of MTA1 expression.

Guo N, Zhang J Am J Cancer Res. 2023; 12(12):5646-5656.

PMID: 36628289 PMC: 9827088.

A Prognostic Impact of Interleukin 17 (IL-17) as an Immune-Marker in Patients with Bladder Cancer.

Mousa F, Jasim H, Shakir F Arch Razi Inst. 2023; 77(3):1059-1065.

PMID: 36618324 PMC: 9759229. DOI: 10.22092/ARI.2022.357801.2098.

The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer.

Huang X, Pan T, Yan L, Jin T, Zhang R, Chen B Genes Dis. 2021; 8(6):781-797.

PMID: 34522708 PMC: 8427242. DOI: 10.1016/j.gendis.2020.10.002.

The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.

Wigner P, Grebowski R, Bijak M, Saluk-Bijak J, Szemraj J Int J Mol Sci. 2021; 22(9).

PMID: 33923108 PMC: 8123426. DOI: 10.3390/ijms22094483.

Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA.

Ding Y, Liu N, Chen M, Xu Y, Fang S, Xiang W World J Surg Oncol. 2021; 19(1):133.

PMID: 33888142 PMC: 8063461. DOI: 10.1186/s12957-021-02231-4.

References

Wang L, Yi T, Kortylewski M, Pardoll D, Zeng D, Yu H . IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009; 206(7):1457-64. PMC: 2715087. DOI: 10.1084/jem.20090207. View

Connolly E, Freimuth J, Akhurst R . Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 2012; 8(7):964-78. PMC: 3399319. DOI: 10.7150/ijbs.4564. View

Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B . Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2011; 62(1):153-9. DOI: 10.1007/s12013-011-9276-3. View

Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L . The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008; 374(3):533-7. DOI: 10.1016/j.bbrc.2008.07.060. View

Murugaiyan G, Saha B . Protumor vs antitumor functions of IL-17. J Immunol. 2009; 183(7):4169-75. DOI: 10.4049/jimmunol.0901017. View

Peck A, Mellins E . Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol. 2009; 132(3):295-304. PMC: 2720426. DOI: 10.1016/j.clim.2009.03.522. View

Chen M, Lin P, Wu C, Chen W, Wu C . IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One. 2013; 8(4):e61901. PMC: 3640078. DOI: 10.1371/journal.pone.0061901. View

Bettelli E, Korn T, Oukka M, Kuchroo V . Induction and effector functions of T(H)17 cells. Nature. 2008; 453(7198):1051-7. PMC: 6280661. DOI: 10.1038/nature07036. View

Jeon S, Chae B, Kim H, Seo G, Seo D, Chun G . Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol. 2006; 81(2):557-66. DOI: 10.1189/jlb.0806517. View

10.

Radosavljevic G, Ljujic B, Jovanovic I, Srzentic Z, Pavlovic S, Zdravkovic N . Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma. 2010; 57(2):135-44. DOI: 10.4149/neo_2010_02_135. View

11.

Passos S, Silver J, OHara A, Sehy D, Stumhofer J, Hunter C . IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J Immunol. 2010; 184(4):1776-83. PMC: 3757499. DOI: 10.4049/jimmunol.0901843. View

12.

Mosmann T, Cherwinski H, Bond M, Giedlin M, Coffman R . Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol. 2005; 175(1):5-14. View

13.

Khatami M . Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem Biophys. 2009; 55(2):55-79. DOI: 10.1007/s12013-009-9059-2. View

14.

Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T . Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol. 2008; 180(11):7175-83. DOI: 10.4049/jimmunol.180.11.7175. View

15.

Kolahdoozan S, Sadjadi A, Radmard A, Khademi H . Five common cancers in Iran. Arch Iran Med. 2010; 13(2):143-6. View

16.

Dong C . TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008; 8(5):337-48. DOI: 10.1038/nri2295. View

17.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J . Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007; 178(11):6730-3. DOI: 10.4049/jimmunol.178.11.6730. View

18.

Zhu X, Mulcahy L, Mohammed R, Lee A, Franks H, Kilpatrick L . IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008; 10(6):R95. PMC: 2656888. DOI: 10.1186/bcr2195. View

19.

Munegowda M, Deng Y, Mulligan S, Xiang J . Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother. 2011; 60(10):1473-84. PMC: 11028972. DOI: 10.1007/s00262-011-1054-y. View

20.

Nam J, Terabe M, Kang M, Chae H, Voong N, Yang Y . Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 2008; 68(10):3915-23. PMC: 2586596. DOI: 10.1158/0008-5472.CAN-08-0206. View